Skip to content

The efficiency of low-dose Prabchompootaweep formulary for allergic rhinitis

The efficiency of low-dose Prabchompootaweep formulary for allergic rhinitis

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20170817002
Enrollment
168
Registered
2017-08-17
Start date
2017-09-01
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis Plant Preparations Allergic rhinitis

Interventions

Comparison of different dosages of drug Patients received one 250mg capsule the Prabchompootaweep Formulary of 23 Thai Herbs which is in the National List of Essential Medicine&#44
1X3 ac. (3 times per day for baseline 3&#44
9&#44
12 days ) and 2X3 ac. (3 times per day for baseline 3&#44
12 days )
Experimental Drug
Prabchompootaweep

Sponsors

Department of thai traditional and alternative medicine,Ministry of Public Health Office
Lead Sponsor
Banlat Hospital
Collaborator

Eligibility

Sex/Gender
All
Age
16 Years to 60 Years

Inclusion criteria

Inclusion criteria: Adult and adolescent with allergic rhinitis symptoms -Need to blow nose -Sneezing -Runny nose -Congestion of nose

Exclusion criteria

Exclusion criteria: Infection of upper respiratory History of allergy to any of the herbs used in this study History of cancer of any kind

Design outcomes

Primary

MeasureTime frame
Optimum treatment duration Before and 3,6,9,12 days after treatment Median day of allergic rhinitis symptom improvement

Secondary

MeasureTime frame
Compare optimum treatment duration between low and very low dose Before and 3,6,9,12 days after treatment Compare median day of allergic rhinitis symptom improvement between low and very low dose

Countries

Banlat

Contacts

Public ContactTamonwan Tabpueng

Thai traditional medicine

gmamam@hotmail.com66929476297

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026